Healthy individuals generally have very small amounts of NMP22 protein in the urine. However, the level of NMP22 protein is often elevated in the urine of patients with bladder cancer, even at early stages of the disease.1 The Alere NMP22 Test is an enzyme immunoassay for the quantitative determination of nuclear mitotic apparatus protein (NuMA) in stabilized voided urine. NuMA is an abundant component of the nuclear matrix proteins (NMP22). The Alere NMP22?BladderChek?Test is the only in-off